Neuro-oncology
Carthera’s clinical research is centered on glioblastoma, with a specific focus on first recurrence glioblastoma and treatment approaches used after surgical management of recurrent disease.
- Glioblastoma recurrence
- Brain tumour treatment
- Post-surgical oncology care
The sponsor’s work in this area reflects interest in improving outcomes for patients with aggressive central nervous system malignancies.
Neurosurgery
Its funded research involves patients undergoing planned surgical resection or debulking, placing neurosurgical intervention at the center of the clinical pathway.
- Resection of brain tumours
- Surgical debulking
- Operative management of recurrent glioblastoma
This indicates a therapeutic interest in the interface between surgery and subsequent oncologic treatment for intracranial disease.
Blood-brain barrier modulation
Carthera’s research includes approaches aimed at blood-brain barrier opening, with attention to enabling treatment delivery within the brain in the setting of recurrent glioblastoma.
- BBB opening
- Intracranial drug delivery
- Device-enabled brain access
The sponsor’s functional name, SonoBird Desk, is linked to this area of therapeutic interest.
Oncology pharmacotherapy
The trial portfolio includes chemotherapy in second-line treatment for recurrent disease, with attention to agents used in high-grade glioma care.
- Carboplatin
- Lomustine
- Temozolomide
This places the sponsor within the therapeutic landscape of recurrent neuro-oncologic treatment and systemic therapy selection.
Multicentre clinical oncology
Carthera’s research activity spans multiple collaborating sites across several countries, reflecting a clinical interest in international oncology care for patients with recurrent brain cancer.
- Multicentre trial conduct
- Cross-border clinical collaboration
- Specialist cancer centre involvement
The sponsor’s current research footprint is concentrated in specialised neuro-oncology networks.
